BioRestorative Therapies Inc Dossier - Source-backed chat

BioRestorative Therapies Inc

BRTXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.82

Intrinsic Value $2.96median of 2 methodsbased on filings through 31 Mar 2026

Market Price $2.27Price as of 1 Oct 2026

UndervaluedIntrinsic value is 30% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $3.1M

Enterprise Value $22.5K

Shares Outstanding 1.4M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

BioRestorative Therapies is a late-stage clinical regenerative medicine company at a critical valuation inflection point. The company's lead candidate, BRTX-100 (an autologous hypoxic-cultured mesenchymal stem cell therapy), has completed Phase 2 dosing for chronic lumbar disc disease, with topline data expected in spring 2027. Blinded interim data presented at ISCT 2026 demonstrated robust efficacy, with 52% of patients achieving over 50% improvement in both pain (VAS) and function (ODI) at 52 weeks. While the company faces near-term liquidity constraints and Nasdaq listing compliance hurdles, its strong clinical progress, FDA Fast Track designation, and the commercial launch of its BioCosmeceuticals platform (BioX) provide a highly asymmetric risk-reward profile for speculative biotech investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$1.00

Mean target$8.00

High · most bullish analyst$15.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.1520%

The company fails to secure additional financing, leading to severe dilution or a restructuring event due to its going-concern status. Delisting from Nasdaq occurs if the minimum bid price is not regained. Clinical development of BRTX-100 is delayed, or the final Phase 2 topline data in 2027 fails to show statistical significance compared to the placebo control group.

Base CaseCentral scenario

$8.0055%

Matches the consensus mean

BRTX-100 successfully transitions into Phase 3 development following IND amendment clearance in late 2026. The company manages its going-concern risk through structured warrant exercises and modest dilutive equity raises, maintaining its Nasdaq listing. Topline Phase 2 data in spring 2027 confirms the positive trends seen in the blinded datasets, positioning the company as an attractive acquisition target for larger orthopedic or biopharmaceutical players.

Bull CaseUpside scenario

$15.0025%

The Phase 2 trial of BRTX-100 yields outstanding topline results in early 2027, meeting or exceeding all primary efficacy endpoints. The FDA grants accelerated approval or a smooth path to BLA submission based on the Phase 3 IND amendment cleared in late 2026. Concurrently, the BioCosmeceuticals division accelerates commercial revenue under newly appointed leadership, significantly reducing the operational cash burn. Strategic licensing partnerships are secured, providing non-dilutive upfront capital and validating the platform.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Completed Phase 2 dosing of BRTX-100, removing clinical enrollment execution risk and setting a clear timeline for topline data in spring 2027.
Strong blinded interim data showing 52% of patients achieved >=50% improvement in both pain and functional metrics at 52 weeks, exceeding the FDA's 30% threshold.
FDA Fast Track designation for BRTX-100 in chronic lumbar disc disease and cleared IND for chronic cervical discogenic pain.
Dual-track strategy with a near-term commercial BioCosmeceuticals platform (BioX) to generate early revenues alongside the high-value clinical pipeline.

Key Investment Risks

Substantial doubt about the company's ability to continue as a going concern, with a cash balance of $3.11M against a quarterly operating cash burn of $3.81M in Q1 2026.
Nasdaq minimum bid price deficiency notice received on March 26, 2026, posing a delisting risk if the stock price does not recover above $1.00.
High dependence on future dilutive equity offerings, warrant exercises, or debt to fund late-stage clinical trials.

Thesis Invalidation Triggers

Failure to clear the Phase 3 IND amendment with the FDA in H2 2026.
Topline Phase 2 clinical data in spring 2027 failing to meet primary efficacy endpoints or showing safety concerns.
Inability to raise capital, leading to insolvency or suspension of clinical programs.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.